Karyopharm Plans to Submit sNDA for Selinexor Plus Ruxolitinib in Myelofibrosis Under Accelerated Approval Pathway
– Company Plans to Submit sNDA in August 2026 and Will Request Priority Review – – Following FDA Engagements, Company Plans to Submit sNDA under Accelerated Approval Based Upon Compelling SVR35 Data and Preliminary Overall Survival Data Observed at the Time of the Topline Results – – Company Plans to Use Long-Term Overall Survival Data from the Ongoing Phase 3 SENTRY Trial to Verify Clinical Benefit – – If Approved, Selinexor in Combination with Ruxolitinib has the Potential to Become the...
How this was made
The 30-second read
Why it matters
If FDA accepts SVR35 as a reasonably likely surrogate endpoint and grants Priority Review, the company’s probability-weighted approval timeline improves, potentially re-rating the stock ahead of the sNDA receipt and subsequent FDA review milestones.
Market read
This is a regulatory-pathway and filing-timing catalyst for KPTI, anchored to FDA feedback on SVR35 and a planned Priority Review request.
What to watch
The article does not provide the magnitude of the overall survival signal, nor any quantified safety tradeoffs for the combination, which could temper enthusiasm if investors focus on confirmatory evidence.
Background
Karyopharm’s XPOVIO (selinexor) is being developed in combination with ruxolitinib for JAKi-naive myelofibrosis; the Phase 3 SENTRY trial is the basis for the planned sNDA.
Ticker impact
Karyopharm plans an August 2026 sNDA for selinexor plus ruxolitinib in myelofibrosis under accelerated approval, using SVR35 as RLSE.
Likely positive near-term bias as traders price higher odds of approval and a Priority Review timeline, with volatility around FDA feedback and sNDA acceptance.
The article discloses a concrete FDA-engagement outcome (SVR35 qualifies as RLSE) plus a specific planned filing month and Priority Review request, which are actionable catalysts for biotech risk/reward.
Market effects
Supports the broader myelofibrosis and oncology regulatory narrative that biomarker-driven endpoints (SVR35) can support accelerated approvals.
Primarily US FDA regulatory pathway, with potential spillover to US-listed biotech sentiment.
Could influence global treatment paradigm expectations for myelofibrosis combination therapy, though the decision is US-focused.
Counterpoint
Accelerated approval based on a surrogate endpoint can still face FDA scrutiny, and confirmatory overall survival verification may take longer than the market expects.
Key entities
- companyKaryopharm Therapeutics Inc.
Plans to submit an August 2026 sNDA for selinexor plus ruxolitinib in myelofibrosis under accelerated approval, requesting Priority Review.
- regulatorFDA
Provided written feedback that SVR35 appears to qualify as a reasonably likely surrogate endpoint to support an accelerated approval sNDA.
- clinical_trialPhase 3 SENTRY trial
Randomized, double-blind Phase 3 study of selinexor plus ruxolitinib versus placebo plus ruxolitinib; co-primary endpoints include SVR35 at week 24 and Abs-TSS change over 24 weeks.
